


## PARP7-IN-12

Cat. No.:	HY-151609
CAS No.:	2819700-92-8
Molecular Formula:	C <sub>23</sub> H <sub>27</sub> ClF <sub>3</sub> N <sub>5</sub> O <sub>5</sub>
Molecular Weight:	545.94
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	PARP7-IN-12 is a potent PARP7 Inhibitor with an IC <sub>50</sub> value of 7.836 nM. PARP7-IN-12 can be used in research of cancer <sup>[1]</sup> .		
IC <sub>50</sub> & Target	PARP7 7.836 nM (IC <sub>50</sub> )		
In Vitro	PARP7-IN-12 (compound 85A; 16-24 h) inhibits cell proliferative with an IC <sub>50</sub> values of 20.722 nM in H1373 cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	PARP7-IN-12 (compound 85A; 3 and 100 mg/kg; i.v. and p.o.; Balb/c mice) has good pharmacokinetic property <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Balb/c mice <sup>[1]</sup>	
	Dosage:	3 and 100 mg/kg	
	Administration:	Intravenous injection (3 mg/kg) and oral administration (10 mg/kg)	
	Result:	Administration i.v. (3 mg/kg)p.o. (100 mg/kg)	
		CL (mL/min/kg)	32
		Vss (L/kg)	0.4
		C <sub>max</sub> (ng/mL)	21733
		AUC <sub>last</sub> (ng·h/mL)	26442
		Oral BA (F%)	48

---

## REFERENCES

---

[1]. Jun LH, et, al. Tricyclic derivatives useful as parp7 inhibitors. WO2022170974.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA